Eli Lilly and Company account plan
Developing medicines for needs
At a glance
Eli Lilly is an Indianapolis pharmaceutical company selling in about 90 countries, with FY2025 revenue of $65,179 million led by Mounjaro and Zepbound.
Eli Lilly and Company, founded in Indianapolis in 1876, discovers, develops, manufactures and markets human pharmaceuticals in a single reportable segment, with products sold in approximately 90 countries. Its portfolio spans cardiometabolic health (Mounjaro, Zepbound, Trulicity, Jardiance), oncology (Verzenio), immunology (Taltz) and neuroscience (Kisunla). FY2025 revenue was $65,179 million, up 45%, with net income of $20,640 million and diluted EPS of $22.95; Mounjaro and Zepbound together accounted for 56% of revenue. Lilly employed approximately 50,000 people at the end of 2025, and David Ricks is Chair, President and CEO.
Business units
Lilly Cardiometabolic Health
about 74% of 2025 revenue (computed)Mounjaro ($22,965 million, +99%), Zepbound ($13,542 million, +175%), Trulicity, Jardiance and insulins, plus the newly launched oral Foundayo (orforglipron) and retatrutide in late development. It reached $18,353 million in Q2 2026, about 80% of the quarter's revenue (computed). Led by Kenneth Custer.
Lilly Oncology
about 14% of 2025 revenue (computed)Verzenio ($5,723 million, +8%), Jaypirca, Retevmo, Inluriyo, Cyramza and Erbitux, with olomorasib and an FRα ADC in Phase 3. Verzenio faces IRA government-set prices from 2028. Led by Jacob Van Naarden, who also heads corporate business development.
Lilly Immunology
about 8% of 2025 revenue (computed)Taltz, Omvoh, Ebglyss and Olumiant for psoriasis, inflammatory bowel disease and atopic dermatitis; other immunology revenue rose to $631 million in the U.S. in 2025. Led by Adrienne Brown.
Lilly Neuroscience
about 2% of 2025 revenue (computed)Kisunla for early symptomatic Alzheimer's disease and Emgality for migraine, with Alzheimer's prevention and alcohol use disorder studies in Phase 3. Led by Carole Ho.
Strategic priorities
- Broaden impact in cardiometabolic health
- Grow incretins through new indications and forms: Foundayo (oral orforglipron) launched in the U.S. for obesity in Q2 2026, retatrutide had 3 positive Phase 3 TRIUMPH trials with a U.S. submission planned for Q1 2027, and about 100 studies run across the class.
- Expand into other therapeutic areas
- Oncology, Immunology and Neuroscience medicines collectively grew 121% in Q2 2026; business development added vaccines, psychiatry, sleep and in vivo CAR-T programs.
- Widen access to obesity medicines
- The Medicare GLP-1 Bridge program gives coverage at $50 per month out of pocket from July 1, 2026 to December 31, 2027, and LillyDirect sells select medicines direct to patients.
- Manufacturing capacity
- A $50 billion capex agenda over five years, with new sites in North Carolina, Wisconsin, Indiana, Virginia, Texas, Alabama, Pennsylvania, Ireland, Germany and the Netherlands.
- 2026 financial guidance
- Revenue of $85 billion to $87 billion, non-GAAP performance margin of 49% to 50.5% and non-GAAP EPS of $35.50 to $36.50.
Latest results
In Q2 2026 Lilly's revenue rose 48% to $22,974 million, on volume +60% partly offset by price -13%, and H1 2026 revenue reached $42,773 million (+51%). Q2 net income was $7,095 million (+25%) and diluted EPS $7.94, held back by $2,776 million of acquired IPR&D. Mounjaro brought $9,943 million (+91%) and Zepbound $4,928 million (+46%); outside-U.S. revenue grew 80% while prices fell 36%, mainly from Mounjaro's addition to China's National Reimbursement Drug List. Lilly raised its 2026 revenue guidance to $85 billion to $87 billion.
Investments and deals
- Manufacturing build-out
- Capex of $7.8 billion in 2025 (vs $5.1 billion), "meaningfully higher" ahead; the first dedicated genetic medicine plant opened in Lebanon, Indiana, and the first commercial batch was produced in Limerick, Ireland.
- 2026 business development
- $13.3 billion paid in 2026 for Centessa, Kelonia, Orna, Ventyx and Ajax; three infectious-disease companies bought in July 2026 for up to $3.9 billion; AtaiBeckley pending at about $2.8 billion.
- 2025 acquisitions
- Verve Therapeutics for $549 million net of cash plus a CVR, Scorpion's STX-478 and SiteOne.
- AI for science
- Lilly is building science foundation models on an Nvidia supercomputer and applying industrial AI to manufacturing data.
Challenges and risks
- Product concentration
- Mounjaro and Zepbound were 56% of 2025 revenue and 65% of H1 2026 revenue.
- Pricing pressure
- IRA government-set prices for Jardiance in 2026 and Trulicity and Verzenio in 2028, lower realized U.S. prices and PBM formulary moves such as CVS Caremark dropping Zepbound as preferred in July 2025.
- Compounded and counterfeit incretins
- Mass-compounded, counterfeit and misbranded incretins remain a stated risk.
- Supply chain and manufacturing scale-up
- Manufacturing scale-up, single-source materials, China-based suppliers, the BIOSECURE Act and tariffs are named risks.
- Rising debt
- Total debt reached $54.9 billion after a $9.0 billion bond issue in May 2026.
What leadership says
“broaden our impact on cardiometabolic health, expand our presence in other therapeutic areas, and invest to drive future growth”
“While we're pleased with our progress this year so far, we're not satisfied.”
“Big often creates inefficiency. So we're very focused on curbing headcount growth”
“We expect to remain active in business development, while maintaining discipline to create value.”
Where a supplier can help
- Manufacturing construction and equipment
- The $50 billion capex agenda and new sites across the U.S. and Europe create demand for engineering, equipment, automation and validation suppliers.
- Supply chain resilience
- Single-source materials and China-based supplier exposure point to alternative sourcing, contract manufacturing and supply-risk tools.
- Direct-to-patient and launch support
- LillyDirect, the Medicare Bridge and the Foundayo launch call for pharmacy, fulfilment, patient-support and DTC marketing partners.
- Integrating acquired companies
- $13.3 billion of 2026 business development across CAR-T, vaccines and psychiatry needs integration, clinical operations and R&D services.
- Industrial AI and data
- Lilly's industrial AI on manufacturing data and science foundation models open room for data, MLOps and compute partners.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Eli Lilly and Company?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Form 10-K for fiscal year 2025
- Eli Lilly and Company (Indianapolis, incorporated 1901, founded 1876) discovers, develops, manufactures and markets human pharmaceuticals in a single reportable segment; products are sold in approximately 90 countries and the company employed approximately 50,000 people at the end of 2025 (approximately 27,000 outside the U.S., approximately 12,000 in R&D).
- FY2025 revenue was $65,179 million, up 45% (volume +50%, price -6%, FX +1%); net income $20,640 million (+95%); diluted EPS $22.95 (+96%); gross margin 83.0% of revenue.
- Mounjaro ($22,965 million, +99%) and Zepbound ($13,542 million, +175%) together accounted for 56% of 2025 revenue; six products above $3 billion each (Mounjaro, Zepbound, Verzenio, Trulicity, Taltz, Jardiance) made 82% of revenue.
- U.S. revenue was $43,481 million (+43%) and outside-U.S. $21,698 million (+48%); Europe $11,558 million, Japan $2,132 million, China $1,951 million, rest of world $6,057 million.
- R&D expense $13,337 million (+21%), marketing, selling and administrative $11,094 million (+29%), acquired IPR&D $2,910 million (Scorpion's STX-478, SiteOne); Verve Therapeutics acquired July 2025 for $549 million net of cash plus a CVR.
- Capital expenditures $7.8 billion in 2025 (vs $5.1 billion) and "meaningfully higher" ahead, with new manufacturing sites in North Carolina, Wisconsin, Indiana, Virginia, Texas, Alabama, Pennsylvania, Ireland, Germany and the Netherlands; total debt $42.5 billion at year-end.
- Pipeline: orforglipron (oral GLP-1) submitted for obesity in the U.S., EU and Japan with a Commissioner's National Priority Voucher; retatrutide, eloralintide, lepodisiran, muvalaplin and many tirzepatide indications in Phase 3.
- November 2025 preliminary agreements with the U.S. government: lower Medicaid prices, balanced launch pricing across developed nations, Medicare access to discounted obesity medicines by July 1, 2026, and a three-year tariff grace period tied to U.S. manufacturing investment.
- Key risks: dependence on incretins, pricing pressure (IRA price setting for Jardiance in 2026, Trulicity and Verzenio in 2028), PBM formulary moves such as CVS Caremark dropping Zepbound as preferred in July 2025, compounded and counterfeit incretins, China competition and supply chain exposure.
- Form 10-Q for the quarter ended June 30, 2026
- Q2 2026 revenue was $22,974 million, up 48% (volume +60%, price -13%, FX +1%); H1 2026 revenue $42,773 million, up 51%.
- Q2 net income $7,095 million (+25%) and diluted EPS $7.94 (+26%), held back by $2,776 million of acquired IPR&D and $703 million of acquisition-related special charges.
- Mounjaro Q2 revenue was $9,943 million (+91%), with $5,152 million outside the U.S.; Zepbound $4,928 million (+46%); Mounjaro and Zepbound were 65% of H1 revenue.
- Outside-U.S. revenue grew 80% in Q2 on 113% volume growth, while price fell 36%, mainly from Mounjaro's addition to China's National Reimbursement Drug List.
- Foundayo (orforglipron) was approved by the FDA and launched in the U.S. for obesity in Q2, and submitted for type 2 diabetes in the U.S., EU and Japan; retatrutide Phase 3 trials met their primary endpoints.
- The Medicare GLP-1 Bridge program gave Medicare beneficiaries access to discounted Lilly obesity medicines from July 1, 2026 to December 31, 2027.
- Business development: $13.3 billion paid in 2026 (Centessa, Kelonia, Orna, Ventyx, Ajax); three infectious-disease companies bought in July 2026 for up to $3.9 billion; AtaiBeckley pending at about $2.8 billion.
- Total debt rose to $54.9 billion after a $9.0 billion bond issue in May 2026; H1 share repurchases $4.0 billion and dividends $3.1 billion.
- Q2 2026 earnings call transcript
- Dave Ricks (Chair and CEO): Q2 "continued Lilly's strong momentum"; revenue +48%, Key Products up almost $6.8 billion, and Oncology, Immunology and Neuroscience medicines collectively +121%.
- 2026 guidance raised: revenue $85 billion to $87 billion, non-GAAP performance margin 49% to 50.5%, non-GAAP EPS $35.50 to $36.50 (CFO Lucas Montarce).
- Foundayo (oral orforglipron) U.S. launch: access at all 3 major PBMs, broad DTC campaign, prescribers up from 8,000 to 36,000, volume "almost doubling" in a month; global rollout in all major markets expected in 2027.
- Medicare GLP-1 Bridge program launched July 1 at $50 per month out of pocket for 20 million eligible Americans; 35% more people now have coverage for Lilly obesity medicines; 60% to 70% of Bridge patients are new to treatment.
- Lilly holds about 6 of 10 U.S. obesity incretin prescriptions and about 55% of the international incretin market; self-pay is about 45% of Zepbound prescriptions.
- Retatrutide: 3 positive Phase 3 TRIUMPH trials; U.S. submission planned for Q1 2027 under the BLA pathway, which is in litigation with the FDA.
- Business development broadened into vaccines (Curevo, LimmaTech, Vaccine Company) and psychiatry (AtaiBeckley), with Centessa, Kelonia and Ajax adding sleep, in vivo CAR-T and JAK programs.
- Manufacturing: first dedicated genetic medicine plant opened in Lebanon, Indiana; first commercial batch produced in Limerick, Ireland.
- The Long View: Interview with Dave Ricks, Chair and CEO, Eli Lilly (The Angle from T. Rowe Price)
- Dave Ricks (Chair and CEO) calls the incretin wave "one of the more important innovation cycles in pharmaceutical history" and sets three priorities: improve access, keep innovating, and build out the indication set.
- He sees obesity as the root of "maybe 40% of chronic disease"; Lilly has about 100 studies running across tirzepatide and other molecules, and 11 drugs of this class in the pipeline.
- Capacity: Lilly committed to a $50 billion capex agenda over five years; about 80% is announced and only 20% operational, which already "fixed the global supply problem for the current demand".
- The White House deal: Medicaid price cuts on some products, new launches at GDP-per-capita-adjusted parity across developed markets, and Medicare obesity coverage at $50 out of pocket, "maybe 20 to 30 million new patients".
- Orforglipron (oral) is "much more scalable", gives weight loss in the "low teens" vs "low 20s" for injectables, and was expected to launch as early as H1 2026 under a priority voucher.
- New areas for incretins: inflammation, brain health and addiction, and possibly cancer; Kisunla prevention study expected to read out in 26 or 27.
- Culture: 11th CEO in 150 years, a consistent end-to-end strategy, and curbing headcount growth to keep the company "intimate".
- AI: enterprise productivity tools are "a little disappointing", "industrial AI" on manufacturing data yields "thousand to one ROI" projects, and Lilly is building science foundation models on an Nvidia supercomputer.
Questions about Eli Lilly and Company
What does Eli Lilly do?
Eli Lilly discovers, develops, manufactures and markets human pharmaceuticals, led by the incretins Mounjaro and Zepbound, plus oncology, immunology and neuroscience medicines.
What is Eli Lilly's revenue?
FY2025 revenue was $65,179 million, up 45%. Lilly guides to $85 billion to $87 billion of revenue for 2026.
How many employees does Eli Lilly have?
Lilly employed approximately 50,000 people at the end of 2025, approximately 27,000 of them outside the U.S.
What is Eli Lilly's strategy?
Broaden its impact on cardiometabolic health, expand into other therapeutic areas and invest in manufacturing, R&D and business development to drive future growth.
Who leads Eli Lilly?
David Ricks is Chair, President and CEO, and Lucas Montarce is CFO.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)